Dantrolene - Cancer Science

What is Dantrolene?

Dantrolene is a muscle relaxant primarily used to treat muscle spasticity and conditions like malignant hyperthermia. It works by interfering with the release of calcium ions from the sarcoplasmic reticulum in muscle cells, thereby reducing muscle contractions.

Is Dantrolene Used in Cancer Treatment?

While dantrolene is not a conventional drug for treating cancer itself, it has garnered interest for its potential applications in oncology. Research is exploring its role in managing cancer-related symptoms and possibly affecting cancer cell physiology.

How Does Dantrolene Affect Cancer Cells?

Studies have indicated that dantrolene may impact cancer cell metabolism by modulating calcium signaling pathways. Calcium ions play a pivotal role in various cellular processes, including proliferation and apoptosis. By disrupting calcium homeostasis, dantrolene might influence cancer cell viability.

Can Dantrolene Help Manage Cancer-Related Symptoms?

Cancer patients often experience muscle spasticity and cramps as side effects of chemotherapy or radiation therapy. Dantrolene can be beneficial in alleviating these symptoms, thereby improving the quality of life for cancer patients.

Are There Any Risks Associated with Using Dantrolene in Cancer Patients?

Like any medication, dantrolene has its side effects, which can include dizziness, weakness, and liver toxicity. Given that cancer patients may already be dealing with a weakened system, it is crucial to carefully monitor and manage these risks under medical supervision.

What Does Current Research Say?

Current research is still in the early stages, primarily focusing on preclinical studies. While the initial findings are promising, more extensive clinical trials are necessary to validate the efficacy and safety of dantrolene in cancer care.

Conclusion

Although not a traditional cancer treatment, dantrolene's potential to manage cancer-related symptoms and affect cancer cell physiology is an exciting area of research. With further studies, dantrolene could become a valuable adjunct in the comprehensive care of cancer patients.

Relevant Publications

Turn Up the Heat: A Case Report of Malignant Hyperthermia During Ambulatory Surgery.

Issue Release: 2024

Dantrolene alleviates mitochondrial dysfunction and neuroinflammation in traumatic brain injury by modulating the NF-ĸβ/Akt pathway.

Issue Release: 2024

Successful Treatment Without Using Dantrolene Sodium on a Child Occurring Malignant Hyperthermia During Induction of General Anesthesia: A Case Report.

Issue Release: 2024

Neuroprotective effects of dantrolene in neurodegenerative disease: Role of inhibition of pathological inflammation.

Issue Release: 2024

Caution for psychiatrists: malignant hyperthermia risks with the anesthetic agent succinylcholine (Suxamethonium) during electroconvulsive therapy.

Issue Release: 2024

Pharmacological and Non-pharmacological Approaches for the Management of Neuropathic Pain in Multiple Sclerosis.

Issue Release: 2024

The Anesthesiologists\' Perception of Malignant Hyperthermia and Availability of Dantrolene in China: A Cross-Sectional Survey.

Issue Release: 2024

Optimization of CHARMM force field parameters for ryanodine receptor inhibitory drug dantrolene using FFTK and FFParam.

Issue Release: 2024

Anaesthesia-related morbidity associated with recumbent, low-field magnetic resonance imaging of horses.

Issue Release: 2024

Review of multiple sclerosis: Epidemiology, etiology, pathophysiology, and treatment.

Issue Release: 2024

Effects of Intranasal Dantrolene Nanoparticles on Brain Concentration and Behavior in PS19 Tau Transgenic Mice.

Issue Release: 2024

Dantrolene and coenzyme Q10 as a suggested combination therapy to statin-induced myopathy in high fat diet rats: A possible interference with ROS/ TGF-β / Smad4 signaling pathway.

Issue Release: 2024

Malignant hyperthermia in a paediatric patient; managed successfully without dantrolene: a case report.

Issue Release: 2024

Ryanodine receptor stabilization therapy suppresses Ca- based arrhythmias in a novel model of metabolic HFpEF.

Issue Release: 2024

Malignant Hyperthermia.

Issue Release: 2024

Dantrolene, a ryanodine receptor stabilizer, is a candidate immunomodulator for treating rheumatic disease.

Issue Release: 2024

The novel rapid formulation of intravenous dantrolene (NPJ5008) versus standard dantrolene (DANTRIUM IV): A clinical part-randomised phase 1 study in healthy volunteers.

Issue Release: 2024

Acute effects of Dantrolene on the mechanical performance of myopathic human hearts.

Issue Release: 2024

Diagnosis and rescue of malignant hyperthermia induced by anesthesia during radical surgery in a cervical cancer patient using the National Remote Emergency System: A case report.

Issue Release: 2024

An inherited life-threatening arrhythmia model established by screening randomly mutagenized mice.

Issue Release: 2024

Are All Baked Goods Harmful?

How is Data Managed and Analyzed in a Cancer Lab?

What are Hierarchical Barriers in Cancer?

Who are the Ideal Candidates?

What Role Does Overtreatment Play?

What are the Common Threats to Cloud Security in Cancer Research?

How Does the MHRA Ensure Continuous Monitoring?

How Does Surface Modification Enhance Targeting Specificity?

How Can Patients and Healthcare Providers Ensure Data Security?

How Does Tobacco Smoke Cause Cancer?

Partnered Content Networks

Relevant Topics